This 2022 rodent study investigated sulforaphane’s effects on airway disease:

“Sulforaphane has been studied in numerous preclinical and clinical models of lung damage and airway diseases. The lack of definitive findings from clinical studies to date most likely reflects issues with extract preparations and dosage regimes.

We investigated effects of administration of L-sulforaphane (LSF), which is also known as (R)-sulforaphane, in a murine model of ovalbumin (OVA)-induced chronic allergic airways disease (AAD). This model of chronic AAD recapitulates several features of human asthma including airway inflammation, airway remodeling, and airway hyper-responsiveness.

Our findings confirmed the efficacy of LSF in attenuating pathologies associated with AAD, involving activation of antioxidant and anti-inflammatory pathways. Inhibition of HDAC enzymes by LSF and accumulation of acetylated core histones and α-tubulin in vivo following LSF administration represent an important epigenetic regulatory mechanism. LSF and its metabolites may modulate HDAC6 and HDAC8 enzymes by binding to the catalytic site.

Our findings along with accumulated evidence, highlight the clinical potential of sulforaphane as either a prophylactic or a therapeutic in the context of AAD.”

https://link.springer.com/article/10.1007/s00018-022-04609-3 “Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms” (not freely available)